LivingGLP1
Study S002813

A Phase II Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight/Obese Patients

ClinicalTrials.gov record

Registration

Registration
NCT07177469
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
DOUBLE
Status
COMPLETED
Enrollment
205
Start
2025-03-14
Primary completion
2025-10-22
Lead sponsor
The United Bio-Technology (Hengqin) Co., Ltd.
Conditions
Obesity &Amp; Overweight
Interventions
DRUG:UBT251 Injection 2.0 mg and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo; DRUG:UBT251 Injection 6.0 mg and UBT251 Injection Placebo
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • Body Weight [Week 24]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0029885UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.
Zhou Z, Cell metabolism
2026Randomized trialPMID 42843337DOIcites ClinicalTrials.gov:NCT07177469; registry reference DERIVED:42843337
R00465783090-LB: UBT251, a Triple Hormone Receptor Agonist in Adults with Overweight or Obesity: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Trial
ZHIGUANG ZHOU, Diabetes
2026Randomized trialDOIcites ClinicalTrials.gov:NCT07177469